REG - Irish Takeover Panel - Disclosure Table
IRISH TAKEOVER PANEL
Disclosure Table
The following companies are deemed to be in an offer period for the purposes of disclosure under the Rules of the Irish Takeover Panel:
_______________________________________________________________
Offeree: Mural Oncology plc
Offer period commenced: 15 April 2025
$0.01 ordinary shares; ISIN: IE000LK2BOB4; NSI: 17,268,881
Offeror: XOMA Royalty Corporation
Disclosure of dealings and positions in this offeror is not required
Offeror identified: 20 August 2025
Rule 2.6(a) deadline: N/A
Offeree: Avadel Pharmaceuticals plc
Offer period commenced: 22 October 2025
$0.01 ordinary shares; ISIN: IE00BDGMC594; NSI: 97,403,364
Offeror: Alkermes plc
Disclosure of dealings and positions in this offeror is not required
Offeror identified: 22 October 2025
Rule 2.6(a) deadline: N/A
Offeror: H. Lundbeck A/S
Disclosure of dealings and positions in this offeror is not required
Offeror identified: 14 November 2025
Rule 2.6(a) deadline: 5:00 p.m. (U.S. Eastern Time) on the seventh day prior to the date of the general meeting of Avadel shareholders convened to consider and approve the proposed scheme of arrangement to effect the proposed acquisition by Alkermes.
Offeree: Permanent TSB Group Holdings plc
Offer period commenced: 30 October 2025
€0.01 ordinary shares; ISIN: IE00BWB8X525; NSI: 544,996,176
Offeror: N/A
Offeror identified: N/A
Rule 2.6(a) deadline: N/A
Irish Takeover Panel 21 November 2025
Lower Ground Floor
76 Merrion Square
Dublin D02 X4T1
Telephone: + 353-1-678 9020
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ISEFZMZMLMNGKZG